Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15570965 | 0.94 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL5663652 | 0.78 | KDM4E (0.60) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL4343120 | 0.78 | SMN1; SMN2 (0.60) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL5535834 | 0.78 | SMN1; SMN2 (0.66) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL118713 | 0.78 | KDM4E (0.60) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL9363173 | 0.78 | KDM4E (0.60) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL676377 | 0.78 | SMN1; SMN2 (0.60) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL82347 | 0.78 | SMN1; SMN2 (0.60) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL4573337 | 0.78 | SMN1; SMN2 (0.60) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL18716535 | 0.78 | SMN1; SMN2 (0.60) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108658878-A | Compound and preparation method thereof based on triazole | 天津师范大学 | 2018-10-16 | — | — | CN | claimed |
| EP-3928836-B1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-09-18 | — | — | EP | disclosed |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-18 | — | — | US | disclosed |
| US-20240101558-A1 | AMPK ACTIVATORS | KALLYOPE, INC. | 2024-03-28 | — | — | US | disclosed |
| US-11851429-B2 | AMPK activators | KALLYOPE, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| CN-116323608-A | AMPK activator | 卡尔优普公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116082369-A | Organic electroluminescent material based on triazolopyridine and organic electroluminescent device | 武汉尚赛光电科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4153589-A1 | AMPK ACTIVATORS | Kallyope, Inc. (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20110190327-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| US-7928230-B2 | Method for modulating GPR119 G protein-coupled receptor and selected compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-19 | — | — | US | disclosed |
| CN-101801956-A | Methods for modulating GPR119G protein-coupled receptors and selected compounds | BRISTOL MYERS SQUIBB CO | 2010-08-11 | — | — | CN | disclosed |
| EP-2173737-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | Bristol-Myers Squibb Company (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090042919-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-12 | — | — | US | disclosed |
| WO-2009012277-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| CN-101171239-A | Electroluminescent device | CIBA SC HOLDING AG (CH) | 2008-04-30 | — | — | CN | disclosed |
| US-5801170-A | Heterocyclic biphenylylamides useful as 5HT1D antagonists | SMITHKLINE BEECHAM PLC (GB) | 1998-09-01 | — | — | US | disclosed |
| EP-0733048-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015954-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, MAPKAPK2, MAP3K20 | SMN1; SMN2 3815/4885KDM4E 688/4885ALDH1A1 4878/4885 |
| US-20110190327-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | GPR119, GPR65, GPR84 | SMN1; SMN2 2497/4885KDM4E 3957/4885ALDH1A1 2395/4885 |
| US-20090042919-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | GPR119, GPR65, GPR84 | SMN1; SMN2 2497/4885KDM4E 3957/4885ALDH1A1 2395/4885 |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | SMN1; SMN2 4553/4885KDM4E 2755/4885ALDH1A1 761/4885 |
| US-11851429-B2 | AMPK activators | PRKAG1, PRKAG2, PRKAG3 | SMN1; SMN2 1174/4885KDM4E 765/4885ALDH1A1 2034/4885 |
| US-20240101558-A1 | AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAG3 | SMN1; SMN2 1174/4885KDM4E 765/4885ALDH1A1 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.